The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

ABSTRACT:

Importance

As Alzheimer disease (AD) research moves to intervene in presymptomatic phases of the disease, we must develop outcome measures sensitive to the earliest disease-related changes.

Objective

To demonstrate the feasibility of a cognitive composite outcome for clinically normal elderly participants with evidence of AD pathology using the ADCS Preclinical Alzheimer Cognitive Composite (ADCS-PACC). The ADCS-PACC combines tests that assess episodic memory, timed executive function, and global cognition. The ADCS-PACC is the primary outcome measure for the first clinical trial in preclinical AD (ie, the Anti-Amyloid Treatment in Asymptomatic Alzheimer's study).

Design, setting, and participants

With the ADCS-PACC, we derive pilot estimates of amyloid-related declin

SUBMITTER: Donohue MC 

PROVIDER: S-EPMC4439182 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature